Ikena Oncology Inc
NASDAQ:IKNA
Market Cap (Intraday) | 62.74M |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $1.31 |
50-Day MA | $1.40 |
200-Day MA | $2.81 |
Ikena Oncology Inc Stock, NASDAQ:IKNA
645 Summer Street, Suite 101, Boston, Massachusetts 02210
United States of America
Phone: +1.857.273.8343
Number of Employees: 43
Description
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.